16. Crow-Fukase syndrome Clinical trials / Disease details

Clinical trials : 13 / Drugs : 18 - (DrugBank : 8) / Drug target genes : 5 - Drug target pathways : 81

6 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02921893 (ClinicalTrials.gov)	October 31, 2016	26/9/2016	Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome	Ixazomib, Lenalidomide, and Dexamethasone for Patients With POEMS Syndrome	Plasmacytoma;POEMS Syndrome	Drug: Dexamethasone;Drug: Ixazomib Citrate;Drug: Lenalidomide;Other: Questionnaire Administration	Mayo Clinic	National Cancer Institute (NCI)	Recruiting	18 Years	N/A	All	34	Phase 2	United States
2	NCT02193698 (ClinicalTrials.gov)	July 2014	16/7/2014	Efficacy and Safety of Lenalidomide as a Treatment for Recurrent or Refractory POEMS Syndrome Trial	Single Arm Open-label Trial to Investigate the Efficacy and Safety of Lenlidomide as a Treatment for Recurrent or Refractory Crow-Fukase (POEMS) Syndrome	POEMS Syndrome	Drug: Lenalidomide +Dexamethasone	Chiba University	NULL	Completed	20 Years	N/A	Both	5	Phase 2	Japan
3	NCT01816620 (ClinicalTrials.gov)	March 2014	14/3/2013	Study to Evaluate Lenalidomide Plus Dexamethasone in Patients With Newly Diagnosed POEMS Syndrome	An Open-label Phase II Study to Determine the Efficacy and Safety of Lenalidomide Plus Dexamethasone (LDex) in Patients With Newly Diagnosed POEMS Syndrome	POEMS Syndrome	Drug: Lenalidomide , Dexamethasone	Peking Union Medical College Hospital	Celgene Corporation	Completed	18 Years	N/A	All	41	Phase 2	China
4	NCT01639898 (ClinicalTrials.gov)	July 2012	5/7/2012	POEMS Syndrome Treatment With Lenalidomide	Phase II Trial With Lenalidomide-Dexamethasone Combination in the Treatment of POEMS Syndrome.	POEMS Syndrome	Drug: Lenalidomide and dexamethasone	University Hospital, Limoges	Ministry of Health, France;Celgene Corporation	Completed	18 Years	N/A	All	51	Phase 2	France
5	EUCTR2008-003202-33-IT (EUCTR)	15/09/2009	17/11/2009	Evaluation of efficacy and safety of Lenalidomide (Revlimid) in patients with POEMS Syndrome - ONC-2008-002	Evaluation of efficacy and safety of Lenalidomide (Revlimid) in patients with POEMS Syndrome - ONC-2008-002	POEMS SYNDROME MedDRA version: 9.1;Level: SOC;Classification code 10029205	Trade Name: REVLIMID *21CPS 25MG INN or Proposed INN: Lenalidomide	ISTITUTO CLINICO HUMANITAS	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Italy
6	NCT00971685 (ClinicalTrials.gov)	July 2009	3/9/2009	The Treatment of Lenalidomide in Patients With POEMS Syndrome	Evaluation of Efficacy and Safety of Lenalidomide (Revlimid®) in Patients With POEMS Syndrome	POEMS Syndrome	Drug: Lenalidomide and dexamethasone	Istituto Clinico Humanitas	NULL	Recruiting	18 Years	N/A	Both	16	Phase 2	Italy